Trial Profile
CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2023
Price :
$35
*
At a glance
- Drugs Inaticabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 13 Dec 2022 Results (n=20; From May 2017 through March 2019) assessing the outcome and long-term follow-up of a pilot study administrating CNCT19 in relapsed or refractory B-cell lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 24 Jan 2022 Status changed from active, no longer recruiting to completed.
- 22 Aug 2019 Planned End Date changed from 1 Nov 2019 to 22 Apr 2021.